Zimmer Biomet Holdings, Inc.(ZBH) 종목 분석 — 적정가치·리스크·해자 평가

Zimmer Biomet Holdings, Inc. (ZBH) stock price is $93.04 as of the latest market close, traded on the NYSE exchange.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. It designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest.

Zimmer Biomet Holdings, Inc. has a market capitalization of $18.20B, classifying it as a large-cap stock in the Healthcare sector.

Zimmer Biomet Holdings, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. It trades on the NYSE under the ticker symbol ZBH.

Based on our valuation model, Zimmer Biomet Holdings, Inc. trades 24.0% below our fair value estimate — potentially undervalued.

• FairValueLabs Fair Value: $122.43
• Current Price: $93.04
• Valuation Zone: Strong Buy Zone

Based on 21 Wall Street analysts, the consensus price target for Zimmer Biomet Holdings, Inc. is $102.95, implying upside of 10.7% from the current price.

• Analyst High Target: $130.00
• Analyst Low Target: $88.00

Note: Analyst targets are shown for reference and are not used in our valuation model.

Here are the analyst consensus growth estimates for Zimmer Biomet Holdings, Inc.:

• Revenue growth (current year est.): 3.9%
• EPS growth (current year est.): 2.4%
• Revenue growth (next year est.): 3.7%
• EPS growth (next year est.): 7.1%

The price-to-earnings ratio measures how much investors pay per dollar of earnings:

• Trailing P/E (last 12 months): 26.2x
• Forward P/E (next 12 months est.): 10.3x
• FairValueLabs Fair P/E: 22.3x

Zimmer Biomet Holdings, Inc. has a beta of 0.61, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.

Zimmer Biomet Holdings, Inc.'s balance sheet shows:

• Total Cash: $620.9M
• Total Debt: $7.87B
• Net Cash Position: $-7.25B

A positive net cash position means the company holds more cash than debt, reducing financial risk.

Zimmer Biomet Holdings, Inc. generated $1.35B in trailing twelve-month free cash flow (from $1.70B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.

Yes, Zimmer Biomet Holdings, Inc. pays a regular dividend. Here are the key metrics:

• Dividend Yield: 1.0%
• Payout Ratio: 27.0%
• Consecutive Years Paid: 15
• 5-Year Dividend Growth: -23.8%
• FairValueLabs Safety Grade: A

Zimmer Biomet Holdings, Inc.'s Altman Z-Score is 2.40, placing it in the gray zone (1.8–3.0) — some financial uncertainty. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.

Zimmer Biomet Holdings, Inc. scores 2.6/5 stars (Narrow moat · eroding) in our moat analysis:

• ROIC Stability: 2/5
• Gross Margin Trend: 3/5
• Switching Costs: 3/5

A score above 3.5 suggests meaningful pricing power and a defensible market position.

Zimmer Biomet Holdings, Inc.'s return on equity is 5.6%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.

ZBH shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:

1. Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
2. Search for ticker symbol ZBH
3. Place a market or limit order for your desired number of shares

This is not investment advice. Always do your own research before buying any stock.

FairValueLabs classifies Zimmer Biomet Holdings, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.

The current CEO of Zimmer Biomet Holdings, Inc. is Mr. Ivan Tornos.

Earnings per share measures the company's profit allocated to each outstanding share:

• Trailing EPS (last 12 months): $3.55
• Forward EPS (next 12 months est.): $8.99
• Analyst consensus EPS (this year): $8.40
• Analyst consensus EPS (next year): $8.99